drugset / Trial / NCT00553813
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the activity of TPI 287 as single agent therapy for patients with advanced, unresectable pancreatic cancer after failure of gemcitabine-containing therapy. Activity of TPI 287 will be determined by the 6-month survival rate.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-09
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPI 287 | Small molecule | 125 mg/m2 | Intravenous |